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Simple Summary: Soft tissue sarcomas are cancerous tumors that can cause death by spreading
throughout the body (metastasizing), most commonly to the lungs. After initial removal of the
tumor, patients undergo periodic chest imaging for 10 years to monitor for metastases, but experts
disagree about whether the abdomen/pelvis should be imaged as well. Our goal was to determine
when, where, and how frequently metastases occur in the abdomen/pelvis; this would help answer
the question of whether these areas should be imaged as part of surveillance. We found that 7%
of patients treated for soft tissue sarcoma developed abdomen/pelvis metastases. Compared to
lung metastases, abdomen/pelvis metastases appeared later and over a broader period of time.
We were not able to predict which patients are most likely to develop abdomen/pelvis metastases.
Understanding these patterns will help experts develop surveillance guidelines that will identify
metastatic cancer without subjecting patients to more scans than necessary.
Abstract: Soft tissue sarcomas (STS) most commonly metastasize to the lungs. Current surveillance
guidelines variably recommend abdominal and pelvic imaging, but there is little evidence to support
this. We sought to determine the proportion of initial pulmonary versus extrapulmonary metas-
tases, the time to development of each, and factors to identify patients that would benefit from
abdominopelvic surveillance. We retrospectively reviewed 382 patients who underwent surgical
treatment for STS at a single institution. Of the 33% (126/382) of patients who developed metastases,
72% (90/126) were pulmonary, 22% (28/126) were extrapulmonary, and 6% (8/126) developed both
simultaneously. Initial extrapulmonary metastases occurred later (log rank p = 0.049), with median
11 months (IQR, 5 to 19) until pulmonary disease and 22 months (IQR, 6 to 45) until extrapulmonary
disease. Pulmonary metastases were more common in patients with high grade tumors (p = 0.0201)
and larger tumors (p < 0.0001). Our multivariate analysis did not identify any factors associated
with initial extrapulmonary metastases. A substantial minority of initial metastases were extra-
pulmonary; these occurred later and over a broader time range than initial pulmonary metastases.
Moreover, extrapulmonary metastases are more difficult to predict than pulmonary metastases,
adding to the challenge of creating targeted surveillance protocols.
Keywords: sarcoma; surveillance; extrapulmonary; metastases
1. Introduction
Soft tissue sarcomas (STS) are a group of rare, histologically diffuse neoplasms of
mesenchymal origin. STS can originate anywhere in the musculoskeletal or peripheral
nervous system, and local treatment typically includes wide resection and radiation.
Even after appropriate management of the primary tumor, STS have the potential to
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metastasize, leading to a mortality rate of 60% in the first five years after treatment [1].
Because of this, post-treatment surveillance is universally practiced, and prognostic factors
such as histologic grade, location, size, and time since treatment are used to dictate the
type and frequency of imaging based on the likelihood of metastases [2,3].
The lungs are the initial site of metastases in 80% of patients who develop distant
disease [4–6], with extrapulmonary metastases occurring less frequently, and often after
pulmonary metastases have been identified [4,7]. Although pulmonary surveillance is
well-accepted, the use of computed tomography (CT) of the abdomen and pelvis for
routine sarcoma surveillance remains controversial, with little evidence to support this
practice [5,6,8,9]. In addition to the relatively low incidence of extrapulmonary metastases,
there are also concerns related to unnecessary diagnostic imaging, including radiation
exposure, incidental findings requiring additional workup, and increased health care
expenditures [10]. Finally, while certain histologic subtypes of STS are linked with increased
risk of extrapulmonary metastases, no other independent prognostic factors have been
identified thus far [6,7]. As such, current guidelines for patients with STS are more variable
and less specific regarding surveillance of the abdomen and pelvis [7,11–14].
Given the uncertain indications for routine extrapulmonary surveillance in patients
with STS, we sought to answer the following questions: (1) Of the patients who developed
metastatic disease following initial treatment, what proportion presented with extrapul-
monary metastases alone compared to pulmonary metastases or both? (2) Was time from
surgery to initial metastasis different for pulmonary versus extrapulmonary metastases?
(3) Can patient characteristics (age, body mass index [BMI] and gender) and pathologic
factors (histologic type, grade, depth, location and size) be used to identify patients at
increased risk for developing pulmonary versus extrapulmonary metastases?
2. Materials and Methods
We performed a retrospective review including all patients who underwent resection
of a non-metastatic STS by one of two orthopedic oncologists at a single sarcoma center
between August 1999 and December 2018. Approval was obtained from the institutional
review board at Washington University School of Medicine, and informed consent was
obtained from all patients. A total of 545 patients with STS received treatment at our
institution during the study period. This included 36 patients with positive margins from
a prior excision who were referred to our institution for definitive surgical treatment.
Thirty-five patients with low grade liposarcomas and 21 patients with metastatic STS at
presentation were excluded. Additionally, 107 patients were lost to follow up within 2 years
of initial treatment and were not known to have died, leaving 382 patients available for
study. (Figure 1) Patients that were lost to follow up were compared with included patients
on the basis of relevant patient and tumor characteristics. The two groups differed in terms
of age, as younger patients were more likely to follow up, and surgical margin status, as
patients with positive margins were more likely to follow up compared to patients with
widely negative (≥5 mm) margins. (Table 1)
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Figure 1. This STROBE flow chart demonstrates the inclusion of patients in this study.
Table 1. Distribution of lost to follow up and included patients’ clinical and tumor characteristics.




Odds Ratio (95% CI) p-Value
Patient Gender 0.66 e
Female 44 (167) 41 (44) -
Male 56 (215) 59 (63) 1.11 (0.72–1.72)
Patient Age (years) b 58.0 (42.0, 70.0) 63.0 (50.0, 76.0) - 0.002 d
Patient BMI (kg/m2)
a 28.9 ± 6.7 28.9 ± 6.9 - 0.98 c
Largest Tumor
Dimension (cm) 7.0 (4.0, 11.3) 7.5 (4.5, 15.0) - 0.34
d
Categorical Tumor Size 0.65 d
≤5 cm 37 (140) 41 (44) -
5–10 cm 32 (123) 30 (32) 0.89 (0.53–1.50)
>10 cm 31 (119) 29 (31) 0.89 (0.53–1.51)
Tumor Location 0.22 e
Lower Extremity 58 (222) 67 (72) -
Upper Extremity 17 (66) 18 (19) 0.89 (0.50–1.58)
Back/Torso/Neck 10 (37) 3 (4) 0.33 (0.11–0.97)
Pelvis/Sacrum 9 (33) 6 (6) 0.56 (0.23–1.39)
Acral (hand/foot) 6 (24) 6 (6) 0.77 (0.30–1.96)
Tumor Depth 0.74 e
Superficial 13 (49) 11 (12) -
Deep 87 (333) 89 (94) 1.15 (0.57–2.48)
Tumor Grade 0.60 d
Low 15 (59) 17 (18) -
Intermediate 2 (7) 3 (3) 1.43 (0.33–6.10)
High 83 (316) 80 (86) 0.91 (0.51–1.62)
Tumor Margins 0.01 d
Positive Margins 28 (106) 22 (23) -
<0.1 cm 23 (89) 18 (19) 0.98 (0.50–1.92)
<0.5 cm 20 (76) 18 (19) 1.09 (0.55–2.16)
≥0.5 cm 29 (108) 42 (45) 1.96 (1.11–3.46)
Data are presented as a mean ± standard deviation for parametric data, or b median (IQR) for nonparametric
data or column % (N). p-values: c = ANOVA, d = Kruskal–Wallis test, e = Fisher’s Exact test.
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Patients were managed according to standard sarcoma treatment and surveillance
guidelines. All patients underwent resection of their primary STS. Adjuvant radiation
therapy was used for high grade tumors and myxoid sarcomas, with the exception of those
that were small and superficial with wide margins, as well as for patients that underwent
amputation with wide margins. Radiation was used for patients with low grade sarcomas
when widely negative margins could not be achieved surgically. Overall, 87% (333/382) of
patients underwent radiation therapy, including 94% (303/323) of patients with high grade
STS and 51% (30/59) of patients with low grade STS. Patients were subsequently followed
by a multidisciplinary sarcoma team consisting of orthopedic, medical and radiation
oncologists. High grade sarcomas were followed every 6 months for 3 to 5 years; while
low grade sarcomas were followed every 6 months until 5 years, then annually thereafter.
Routine surveillance included physical examination, local magnetic resonance imaging
(MRI), and CT of the chest, abdomen and pelvis, with occasional use of positron emission
tomography (PET) in conjunction with CT if indicated. Potential metastatic findings on
surveillance imaging received shorter-interval follow up and/or biopsy as indicated.
2.1. Variables and Outcome Measures
Pulmonary metastases were confined to the lung parenchyma and pleura, while
metastases occurring in any other visualized tissue were considered extrapulmonary.
Diagnoses of metastases were confirmed with imaging or biopsy. Independent variables
related to the primary tumor included depth, size, grade, histopathology, location and
surgical margins. Tumor depth was characterized relative to investing fascia. Tumor sizes
were based on their greatest dimension and categorized into three groups: ≤5 cm, 5 to
10 cm, and >10 cm. All STS were graded as low, intermediate, or high based on the French
Federation of Cancer Centers Sarcoma Group (FNCLCC) system, and tumors were grouped
according to histologic type (Table 2). Finally, surgical margins were categorized into four
groups that represented: positive margins, malignancy at <0.1 cm from the nearest margin,
malignancy at <0.5 cm from the nearest margin, and malignancy at ≥0.5 cm from the
nearest margin.








Patient Age (years) b 58.0 (42.0–70.0)
Patient BMI (kg/m2) a 28.9 ± 6.7
Largest Tumor Dimension (cm) 7.0 (4.0–11.3)
Categorical Tumor Size
≤5 cm 37 (140)
5–10 cm 32 (122)
>10 cm 31 (120)
Tumor Location
Lower Extremity 58 (222)


















Positive Margins 28 (106)
<0.1 cm 23 (89)
<0.5 cm 20 (76)
≥0.5 cm 29 (108)
Tumor Histopathology
Undifferentiated Pleomorphic Sarcoma 30.4 (116)
Leiomyosarcoma 17.3 (66)
Fibrosarcoma 11.5 (44)
Sarcoma, Unspecified 9.7 (37)
Synovial Sarcoma 8.1 (31)
Liposarcoma 6.5 (25)
Myxoid Liposarcoma 4.7 (18)
Malignant Peripheral Nerve Sheath Tumor 3.1 (12)
Epithelioid Sarcoma 1.6 (6)
Rhabdomyosarcoma 1.6 (6)
Chondrosarcoma/Osteosarcoma 1.3 (5)
Ewing/Round Cell Sarcoma 1.3 (5)
Alveolar/Embryonal Rhabdomyosarcoma 1.0 (4)
Alveolar Soft Part Sarcoma 0.8 (3)
Angiosarcoma 0.8 (3)
Hemangiopericytoma 0.3 (1)
Time to metastasis (months) b -
Length of follow-up (months) b 44.9 (26.8–75.5)
Data are presented as a mean ± standard deviation for parametric data, or b median (IQR) for nonparametric
data or column % (n).
2.2. Demographics and Description of Distant Metastases
Thirty-three percent (126/382) of patients developed distant metastases. The distribu-
tion of location for initial metastases was: 72% (90 patients) pulmonary, 22% (28 patients)
extrapulmonary, and 6% (8 patients) with simultaneous pulmonary and extrapulmonary
metastases. The median age of patients at the time of diagnosis with extrapulmonary
metastases was 59 years (IQR, 44 to 73) versus 60 years (IQR, 40 to 71) for pulmonary
metastases. Eighteen patients with extrapulmonary metastases died of their disease, seven
within 24 months of initial treatment. The median length of follow-up for patients with
extrapulmonary metastases was 38 months (IQR, 22 to 79). (Table 3).











(years) b 57.5 (39.3–67.8) 59.0 (45.0–69.0) - 0.41
d
Patient BMI





7.1 (4.6–10.2) 8.5 (6.0–12.5) - 0.12 d











Categorical Tumor Size 0.26 d
≤5 cm 29 (8) 16 (14) -
5–10 cm 46 (13) 46 (41) 0.59 (0.21–1.72)
>10 cm 25 (7) 39 (35) 0.38 (0.12–1.22)
Tumor Location 0.69 e
Lower extremity 54 (15) 60 (54) -
Upper extremity 18 (5) 14 (13) 1.41 (0.43–4.58)
Back/torso/neck 7 (2) 11 (10) 0.73 (0.14–3.71)
Pelvis/sacrum 18 (5) 9 (8) 2.29 (0.65 to 8.04)
Acral
(hand/foot) 4 (1) 6 (5) 0.73 (0.08 to 6.76)
Tumor Depth 0.13 e
Superficial 18 (5) 6 (5) -
Deep 82 (23) 94 (85) 3.04 (0.67 to13.21)
Tumor Grade 0.67 d
Low 11 (3) 7 (6) -
Intermediate - 1 (1) -
High 89 (25) 92 (83) 0.70 (0.17–2.92)
Tumor Margins 0.26 d
Positive 29 (8) 20 (18) -
<0.1 cm 36 (10) 27 (24) 0.94 (0.31 to 2.85)
<0.5 cm 7 (2) 22 (20) 0.22 (0.04 to 1.20)
≥0.5 cm 29 (8) 31 (28) 0.62 (0.20 to 1.95)
Months to
metastasis b 22 (6–45) 11 (5–19) - 0.08
d
Months of





30 (12–48) 24 (13–39) - 0.31 d
Data are presented as a mean ± standard deviation for parametric data, b median (IQR) for nonparametric data,
or column % (n). p-values: c = ANOVA, d = Kruskal–Wallis test, e = Fisher’s Exact test.
Twelve out of 15 histologic subtypes had development of initial extrapulmonary metas-
tases. Eighty-nine percent (25/28) of tumors were high grade and 82% (23/28) were deep
to the investing fascia. The most common locations for initial extrapulmonary metastases
were the lymph nodes and appendicular bone, followed by the liver. (Table 4) Out of the 36
initial extrapulmonary metastases that were detected, 19 were found with abdominopelvic
CT and 12 were found with routine chest CT. The remaining 5 extrapulmonary metastases
were in the head and distal extremities, and were detected using extremity MRI, whole
body PET or head CT.
Table 4. Locations of extrapulmonary metastases.
Location % (n)
Lymph Node 25 (9)
Bone, Appendicular 25 (9)
Liver 14 (5)
Bone, Axial 8 (3)
Chest Wall 5 (2)
Adrenal Gland 5 (2)
Spleen 3 (1)
Pancreas 3 (1)
Small Bowel 3 (1)
Brain 3 (1)
Muscle 3 (1)
Femoral Vein 3 (1)
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2.3. Statistical Analysis
To answer our first study question, the proportion of patients who developed initial
extrapulmonary metastases was determined. A binomial proportion test was performed to
compare the proportion of patients with metastatic STS who developed initial extrapul-
monary versus initial pulmonary metastases.
To answer our second study question, whether there was a difference in time to extra-
pulmonary versus pulmonary metastases following primary tumor resection, a Kaplan–
Meier curve was created, and a log rank test was used to compare metastases-free survival
between these groups. Median time to initial metastases for each group was also calculated
and compared using a Kruskal–Wallis test.
To answer our third study question, whether the development of initial extrapul-
monary metastases was associated with clinically relevant factors (patient age, BMI, and
gender, tumor grade, depth, location, histologic type and size) or a combination of these
variables, a t-test or Kruskal–Wallis test (as appropriate) was performed for continuous
variables, and a chi-square test (or Fischer’s exact test for comparisons with inadequately
populated cases) was performed for categorical variables.
To address transfer bias in our study, included patients were compared to those who
were lost to follow up in terms of tumor (size, location, grade, depth, surgical margins)
and patient (age, gender, BMI) characteristics. This analysis was performed using t-tests
or Shapiro–Wilk tests for continuous variables, and chi-square or Fisher exact tests for
categorical variables. Median age was greater in patients who were lost to follow up than
those who were included in the study 63 (IQR, 50 to 76) and 58 (IQR, 42 to 70), respectively;
p = 0.002)), and, patients with widely negative margins were more likely to be lost to follow
up than patients with positive margins [Odds Ratio (OR) = 1.96, 95% confidence interval
(CI): 1.11–3.46, p < 0.01] (Table 1).
SPSS statistical software (IBM Corp, Armonk, NY, USA) was used to perform all statistical
analyses. A significance threshold of 0.05 was considered to be statistically significant.
3. Results
3.1. Incidence of Initial Extrapulmonary Metastases
Thirty-three percent (126/382) of patients developed distant metastases. Of these,
72% (90/126) had initial metastatic disease located in the lungs, while 22% (28/126) had
extrapulmonary metastases. The remaining 6% (8/126) of patients were found to have
simultaneous pulmonary and extrapulmonary metastases. These results show that ini-
tial extrapulmonary metastases occur less commonly than initial pulmonary metastases
(binomial proportion 0.22 [95% CI 0.15 to 0.30]; p < 0.001).
3.2. Time to Development of Initial Extrapulmonary Metastases
Initial extrapulmonary metastases occurred later than initial pulmonary metastases
(log rank p = 0.049) (Figure 2). Median time from surgical treatment to development of
metastases was 11 months (IQR, 5 to 19) for isolated pulmonary and 22 months (IQR, 6 to
45) for isolated extrapulmonary disease (p = 0.08) (Table 3).
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Figure 2. Kaplan–Meier curves for metastasis-free survival demonstrate that initial extrapulmonary
metastases occurred later than initial pulmonary metastases (log rank p = 0.049).
3.3. Association of Relevant Patient and Tumor Characteristics with Extrapulmonary Metastases
Our multivariate regression was unable to detect independent prognostic factors that
would be useful in identifying patients at an increased risk of developing new extrapul-
monary metastases. Patients with high grade tumors were at a greater risk of developing
pulmonary metastases compared to those with low grade tumors [OR = 2.916, 95% CI:
1.183–7.191, p = 0.0201]. In addition, increasing tumor size was found to correlate with
an increased incidence of new pulmonary metastases (OR = 4.414, 95% CI: 2.245–8.680,
p < 0.0001 for tumor size <5 cm versus 5–10 cm; OR = 3.530, 95% CI: 1.778–7.008, p = 0.0003
for tumor size <5 cm versus >10 cm) (Table 5).
Table 5. Odds ratio estimates with 95% confidence intervals and p-value from the multivariate model
on pulmonary metastases.
Parameter (Reference) Odds Ratio (95% CI) p
Tumor Grade
High (Low) 2.92 (1.18–7.19) 0.02
Categorical Size
5–10 cm (<5 cm) 4.41 (2.25–8.68) <0.001
>10 cm (<5 cm) 3.35 (1.78–7.01) <0.001
BMI (kg/m2) 1.04 (1.00–1.08) 0.03
4. Discussion
Surveillance following initial treatment is considered an essential component of sar-
coma management. The goal is to detect recurrent or metastatic disease in order to provide
patients with prognostic information and treatment. Sarcomas most commonly metasta-
size to the lungs, so the importance of pulmonary surveillance is universally accepted;
however, extrapulmonary surveillance remains controversial. This knowledge gap has
led to differences in surveillance recommendations and practices between geographic
regions and among individual providers. We sought to build on the existing literature
by studying a large cohort of STS patients to better define the incidence and timing of
extrapulmonary metastases, as well as any factors that could identify patients more likely to
develop extrapulmonary metastases and therefore benefit from abdominopelvic imaging.
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4.1. Limitations
There are several limitations to this work. First, while our study found that rou-
tine abdominopelvic imaging may lead to earlier diagnosis of metastases, it was not
designed to assess potential morbidity and mortality benefits of extrapulmonary imaging.
While metastatic STS was historically considered untreatable, strategies for managing
systemic disease have emerged over recent decades with novel immunotherapy modalities
being particularly exciting [15]. Research on pulmonary metastasectomy has shown an
association between fewer pulmonary nodules, greater resectability, extended disease-free
interval, and improved survival [8,16]. Studies evaluating locally ablative modalities,
such as stereotactic body radiotherapy and cryoablation, have also produced promising
results in improving progression-free survival and local control of pulmonary metastases.
These modalities may play a future role in treatment for extrapulmonary metastases due to
their quicker recovery times and greater accessibility to lesions in the bone, liver, and vis-
ceral sites compared to surgical intervention [17,18]. However, we are not aware of any data
demonstrating clear morbidity and mortality benefits to early treatment of extrapulmonary
disease. Other relevant issues, such as the time and cost associated with closer surveillance,
are also beyond the scope of this study—as such, we cannot draw definitive conclu-
sions or recommendations about whether abdominopelvic imaging should be included in
routine surveillance.
Second, because sarcoma is an uncommon disease and extrapulmonary metastases are
even more rare, our sample size was limited. This may have caused our analysis to be under-
powered with respect to detecting associations between the clinicopathological variables in our
multivariate model and the development of new extrapulmonary metastases.
Our study was also limited by its retrospective design in several respects. Each follow-
up visit included physical examination, chest CT, and local MRI, in accordance with current
guidelines. The lack of clear recommendations for extrapulmonary surveillance may have
led to more variable acquisition of abdominal and pelvic CT. This may have resulted in a
sampling bias, with some patients developing extrapulmonary metastases that were not
imaged before their pulmonary metastases were diagnosed; in this case, our results would
underestimate the frequency of initial extrapulmonary disease. Transfer bias limited our
study as well, as 22% of patients received less than 2 years of follow-up and were excluded
from the analysis. Older patients were more likely to be lost to follow up, although the
difference of median 63 compared to 58 years is not likely to be clinically significant in this
context. Patients with widely negative (>0.5 cm) surgical margins were also more likely to
be lost to follow up compared to those with positive margins. A potential explanation for
this could be that patients with positive surgical margins were aware of their higher risk
for recurrence, causing them to be more consistent with follow up. As we did not identify
any risk factors for extrapulmonary metastases, we have no indication of how this may
have changed our findings. Finally, the evolution of sarcoma treatment over the course of
our 20-year study period may have led to co-treatment bias; however, given the complexity
of these factors and their intersectionality, we are unable to determine their effect on
our results.
4.2. Existing Literature
4.2.1. Proportion of Initial Extrapulmonary Metastases
Our study found that 33% of patients developed distant metastases after resection of
their primary STS. Within this group, 22% were initially diagnosed with extrapulmonary
metastases, while an additional 6% of patients were found to have simultaneous pulmonary
and extrapulmonary metastases. The overall frequency of distant metastases in our patient
population is comparable with that reported in the literature, which ranges between 20%
and 40% [2,4,5,7,9,19–22]. The rarity of this condition has limited prior studies, thus con-
tributing to the lack of evidence-based guidelines. The majority of existing studies report
20 or fewer incidences of isolated extrapulmonary metastases, averaging approximately
5% of all STS patients [2,4–7,22–24]. Because of these low numbers, authors have gener-
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ally refrained from providing recommendations regarding extrapulmonary surveillance.
Some have concluded that routine imaging of the abdomen and pelvis is difficult to support
given the low incidence of initial extrapulmonary metastases and the interplay of other
variables such as cost of imaging, as well as complications associated with false positives
and related work-up [7,24]; others have recommended that all patients be given the option
to receive CT of the abdomen and pelvis as part of their regular follow-up.
Studies on STS patients followed with CT of the chest, abdomen, and pelvis have
found that extrapulmonary metastases are rare relative to pulmonary metastases, and
they tend to occur after pulmonary metastases have been detected. One study reported
that 10% (14/140) of patients had abdominal or pelvic metastases; however, only four
of these patients first developed isolated extrapulmonary metastases, while the other 10
patients developed extrapulmonary metastases after pulmonary metastases had already
been diagnosed [7]. The other study reported that 16% (20/124) of patients developed
extrapulmonary metastases, but only seven patients had initial extrapulmonary metastases.
These studies found the incidence of initial extrapulmonary metastases to be 3% and 6%,
respectively, compared to the 7% incidence we observed. An additional eight patients in
our study were initially diagnosed with pulmonary and extrapulmonary metastases, making it
unclear which developed first. Also of note, 12 of the 36 initial extrapulmonary metastases were
detected on chest CT, so it would have been identified without abdominopelvic imaging.
Although low compared to the frequency of pulmonary metastases in STS patients,
a 7% incidence has warranted surveillance in other malignancies. For example, asyn-
chronous lung metastases occur in 1.7% to 7.2% of patients with colorectal cancer [25],
and surveillance guidelines for this population generally include routine CT of the chest
every 6 to 12 months for the first 3 to 5 years after surgery [26,27]. In patients with stage IV
colorectal cancer, resection of pulmonary metastases is not curative but has been shown to
significantly improve 5-year survival (13.8% in all patients with pulmonary metastases, but
32–61% in patients able to undergo pulmonary metastectomy) [25]. A similar improvement
in survival has not been clearly defined for resection of extrapulmonary STS metastases,
although new advances in treatment have shown promising preliminary results [15,17,18].
Overall, our findings suggest that abdominal and pelvic imaging in routine surveil-
lance may lead to earlier diagnosis of metastases in a substantial minority of patients.
Of note, the incidence of initial extrapulmonary metastases in STS is comparable to that
of metastases routinely screened for in other cancers; however, a clear survival benefit of
early detection of extrapulmonary metastases in STS has not yet been demonstrated.
4.2.2. Time to Development of Initial Extrapulmonary Metastases
Our study found a longer interval of metastases-free survival between patients who
developed initial extrapulmonary compared to pulmonary metastases. The median time
from surgical treatment to diagnosis of initial extrapulmonary metastases was twice that
of initial pulmonary metastases (22 and 11 months, respectively); moreover, the IQR was
over twice as broad for median time to extrapulmonary metastases (6 to 45) compared to
pulmonary metastases (5 to 19).
Prior literature on the timing of metastatic diagnosis in STS has focused on pulmonary
disease. Most of these metastases are identified within the first two years of STS diagnosis,
especially in patients with high grade tumors [14,22,24,28]; hence, the NCCN and ESMO
surveillance guidelines recommend more frequent imaging in the first 2–3 years for patients
with high and intermediate grade STS. [12,13]. However, these intervals may not accurately
reflect the timing for extrapulmonary metastases. Thompson et al. reported an average
time to isolated extrapulmonary metastases of 12 months among four patients; this is only
half the time we observed, but the discrepancy may be related to the small number in
their study and the large range of time to extrapulmonary metastases in ours. Among the
28 patients with isolated extrapulmonary metastases in our study, the median time to
diagnosis was 22 months after surgery; moreover, 25% of these initial metastases were not
diagnosed until ≥45 months. Thus, while extrapulmonary metastases were less common,
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they were also less predictable in terms of timing, which limits the development of targeted
surveillance strategies.
4.2.3. Factors Associated with Extrapulmonary versus Pulmonary Metastases
Previous studies have found increased depth, higher grade, larger size, and shorter
length of the disease-free interval to be associated with distant metastases in general [5,9,29],
but not specifically to extrapulmonary metastases. To our knowledge, there are no prior
studies which have investigated prognostic factors for the development of extrapulmonary
metastases in STS. While our data confirmed that patients with larger, higher grade tumors
experienced an increased incidence of new pulmonary metastases, we were unable to
identify patient or tumor variables that could be used to identify patients with an increased
risk of developing extrapulmonary metastases. Specifically, our multivariate analysis did
not detect an association between patient age, gender, BMI, tumor size, depth, grade,
location, or histologic subtype with development of initial extrapulmonary metastases.
Thus, although higher grade and larger size have been widely linked to increased risk of
metastases in STS [6,19–21,29], we did not observe either of these variables to be associated
with initial extrapulmonary metastases.
Prior studies have demonstrated a relatively high incidence of extrapulmonary metas-
tases in patients with myxoid liposarcomas. Estourgie et al. and Muratori et al. found
that 55% of metastases in patients with myxoid liposarcomas were extrapulmonary, and
both groups of authors emphasized the importance of routine extrapulmonary imag-
ing for surveillance [30,31]. Current NCCN guidelines name angiosarcomas, epithelioid
sarcomas, leiomyosarcomas, and myxoid liposarcomas as histologic subtypes with in-
creased frequency of extrapulmonary metastases [13] but do not cite evidence supporting
this recommendation. While we did not detect increased risk associated with histologic
subtype in our multivariate analysis, 67% (2/3) of angiosarcoma patients, 17% (1/6) of
epithelioid sarcoma patients, and 17% (3/18) of myxoid liposarcomas patients developed
initial extrapulmonary metastases; by contrast, only 3% (2/66) of patients with metastatic
leiomyosarcomas had initial extrapulmonary metastases. While histologic diagnosis did
not reach significance in our regression model, the high incidence of initial extrapulmonary
metastases among patients with certain sarcoma subtypes warrants further investigation
in a larger patient population.
5. Conclusions
Of the 33% of patients with primary STS that developed metastatic disease after re-
section, 22% were initially diagnosed with extrapulmonary metastases, and an additional
6% with simultaneous pulmonary and extrapulmonary metastases. Initial extrapulmonary
metastases occurred later and over a broader time range than pulmonary metastases.
While patients with larger, higher grade tumors were more likely to develop pulmonary
metastases, we were unable to identify patient or tumor variables that were associated
with an increased risk of extrapulmonary metastases. These findings suggest that routine
abdominal and pelvic imaging may detect new metastatic disease in a substantial minority
of patients. Future studies with larger numbers may identify risk factors for extrapul-
monary disease, but at this time we are unable to predict which, if any, patients are more
or less likely to benefit from routine abdominopelvic imaging. Further research is needed
to evaluate the potential advantages of early detection of extrapulmonary metastases on
treatment and survival. Additionally, better understanding the psychosocial impact of
increased imaging, the potential morbidity of investigating false positive findings, and
the overall cost-effectiveness of advanced imaging will be necessary to develop definitive
surveillance recommendations.
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